The increased expression of RCC2, likely due to aberrant methylation, associated with “early recurrence” allele [A] in our study, adds further support for a putative oncogenic mechanism of this gene, possibly contributing to worse clinical outcomes and melanoma progression. The gene discussed is RCC2; the disease is melanoma.